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Sentrin specific proteases (SENPs) are responsible
for activating and deconjugating SUMO (Small Ubiq-
uitin-like MOdifier) from target proteins. It remains
difficult to study this posttranslational modification
due to the lack of reagents that can be used to block
the removal of SUMO from substrates. Here, we
describe the identification of small molecule SENP
inhibitors and active site probes containing aza-
epoxide and acyloxymethyl ketone (AOMK) reactive
groups. Both classes of compounds are effective
inhibitors of hSENPs 1, 2, 5, and 7 while only the
AOMKs efficiently inhibit hSENP6. Unlike previous
reported peptide vinyl sulfones, these compounds
covalently labeled the active site cysteine of multiple
recombinantly expressed SENP proteases and the
AOMK probe showed selective labeling of these
SENPs when added to complex protein mixtures.
The AOMK compounds therefore represent prom-
ising new reagents to study the process of SUMO
deconjugation.
INTRODUCTION
The small ubiquitin-like modifier (SUMO) is an 11 kDa protein
that is conjugated to various target proteins in order to alter
their function (for reviews, see Drag and Salvesen, 2008;
Geiss-Friedlander and Melchior, 2007; Kim and Baek, 2009).
SUMO, like the structurally related ubiquitin protein modifier,
is attached to substrate proteins through an isopeptide linkage
to a lysine residue. This posttranslational process is orches-
trated by a series of conjugating enzymes that activate and
transfer the SUMO to the target protein. Prior to entering into
the conjugation pathway, SUMO must first be proteolytically
processed from a pro-form by the action of a SUMO-specific
protease (SENP). SENP proteases also remove SUMO from
a target to complete the cycle. The functional relevance of722 Chemistry & Biology 18, 722–732, June 24, 2011 ª2011 ElsevierSUMO modification of proteins is still poorly understood.
Studies of specific SUMO-modified proteins have revealed
possible roles in the regulation of protein-protein interaction
(Pfander et al., 2005), transcription (Desterro et al., 1998),
protein localization (Matunis et al., 1996), and more recently
heat shock (Golebiowski et al., 2009). However, it has been
difficult to generalize these examples to draw conclusions
about target recognition, selectivity, and the mechanisms con-
necting SUMO modification to downstream phenotypes. There-
fore, there has been much interest in the development of tools
to globally characterize SUMOylation events using biochemical
methods. These efforts have provided valuable clues as to the
significance of SUMO modification (Desterro et al., 1998; Gole-
biowski et al., 2009; Gostissa et al., 1999; Ulrich, 2009).
However, because of the highly dynamic nature of SUMO
modification, it has remained difficult to globally assess the
temporal aspects of SUMOylation in the regulation of basic bio-
logical processes.
Surprisingly, very few small molecule tools have been devel-
oped for exploring this class of protease. Currently, only inhibi-
tors based on full-length or truncated forms of SUMO containing
a reactive functional group at the C-terminal glycine residue have
been described. Covalent inhibitors containing vinyl sulfone (VS)
or mechanistically similar vinyl methyl ester (VME) reactive
groups have been reported (Borodovsky et al., 2005; Hemelaar
et al., 2004). The commercially available full-length SUMO vinyl
sulfone inhibitor has also been developed into an active site
probe by addition of an HA tag at the N terminus to allow detec-
tion bywestern blotting (Wilkinson et al., 2005). In addition, a bio-
tinylated vinyl sulfone-based inhibitor containing the final five
amino acids of the C terminus of SUMO was shown to label at
least one protein in cell lysates in a dose-dependent manner
(Borodovsky et al., 2005). Labeling of this protein could also be
competed away by addition of full-length SUMO. However, the
identity of the target has never been confirmed.
Recently, we screened a library of cysteine protease inhibi-
tors in lysates of the human parasite pathogen Plasmodium
falciparum to identify compounds that blocked endopeptidase
processing of recombinant ProSUMO (see Ponder et al., 2011
[this issue of Chemistry & Biology]). This previously described
library (Arastu-Kapur et al., 2008) contained 508 inhibitorsLtd All rights reserved
Figure 1. Activity of Initial Lead Compounds
against hSENP1 Using the ProSUMO Pro-
cessing Assay
(A) Purified recombinant DNhSENP1 (100 nM)
was pretreated with JCP665, JCP666, JCP667,
or JCP668 (0–100 mM) for 30 min at room
temperature followed by addition of ProhSUMO1
substrate. Cleavage of ProhSUMO1 was as-
sessed by SDS-PAGE and visualized by Gelcode
Blue protein stain reagent. ProhSUMO1 alone was
included as a control in the lanes labeled (C).
(B) Activity of the first-generation analog of
JCP666 lacking the aza-aspartic acid side chain
on the azide nitrogen. VEA260 was measured
using the same assay conditions outlined in (A).
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ibly inhibit proteases. The screen yielded one lead compound
JCP666, that contained a reactive aza-epoxide electrophile
linked to an extended, nonnatural peptide backbone structure
that effectively blocked PfSENP activity. In this study, we
describe the application and further development of this lead
series of compounds to human SENPs. Furthermore, we
describe the design, synthesis, and optimization of a second
class of inhibitor that contains the acyloxymethyl ketone
(AOMK) reactive group. The data from these two compound
classes provided an initial SAR series that resulted in the iden-
tification of compounds that covalently inhibit the catalytic
domain of multiple hSENPs. Our best lead compounds were
also converted to labeled analogs and used as activity-based
probes. These new reagents will likely have value in the further
study of SENP function.
RESULTS AND DISCUSSION
Evaluation of aza-epoxides as Inhibitors
of Human SENPs
Our recent screen for inhibitors of the primary SENP from
Plasmodium falciparum identified one lead compound, JCP666,
that contains a reactive aza-epoxide electrophile with a nonnat-Chemistry & Biology 18, 722–732, June 24, 2011ural peptide backbone (Figure 1A). We
also identified three structurally related
analogs of JCP666 that differed either in
the type of reactive electrophile or in the
size of the aromatic groups linked to the
reactive electrophile. Structure activity
relationship (SAR) studies of these four
compounds against the parasite SENP1
indicated that conversion of the aza-
epoxide (JCP666) to an aza-acrylamide
(JCP668) resulted in a modest loss of
potency. Furthermore, reduction in the
size of the aromatic groups attached at
one end of the epoxide moiety resulted
in a more dramatic loss in potency. Since
these compounds were not initially tested
against the human SENP proteases, we
initially set out to evaluate their activity
against the catalytic domain of recombi-nantly expressed human SENP1. To assess activity, we used
a ProSUMOprocessing assay thatmakes use of a recombinantly
expressed hSUMO containing the full proSUMO sequence with
the addition of a C-terminal His6x tag. Since removal of the
pro-region and the His6x tag results in a significant shift in the
molecular weight of the SUMO protein, it is possible to monitor
cleavage by simple SDS-PAGE analysis (Figure 1A). As expected
basedon the homology of parasite andhumanSENP1proteases,
the three original aza-epoxides from the library screen showed
virtually identical SAR profiles as those observed for PfSENP1.
We recently found that the aza-aspartic acid epoxides containing
the bulky di-naphthyl amidewere found to be somewhat suscep-
tible to ring opening of the epoxide in aqueous media (Ponder
et al., 2011 [this issue of Chemistry & Biology]). We found that
removal of the aspartic acid side chain to generate VEA260 re-
sulted in a more stable compound that also retained full activity
against hSENP1 (Figure 1B). Importantly, this compound showed
comparable potency to the original JCP666 lead. We therefore
proceeded with this general scaffold for the rest of our SAR
studies of the aza-epoxide containing compounds.
Design and Synthesis of Epoxide Inhibitor Library
Because our initial small SARstudy confirmed that large aromatic
groups were required at one end of the epoxide electrophile,ª2011 Elsevier Ltd All rights reserved 723
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lead compound VEA260. Although VEA260 does not contain
standard amino acids in the main backbone, it contains two
amide linkages that are likely to represent the classical P2 and
P3 residues of peptide-based inhibitors. We therefore started
out synthesizing a library of compounds in which either the P2
or P3 residue was replaced by a series of natural and nonnatural
amino acids (Figure 2A). In total, we synthesized six P2
compounds and nine P3 compounds.
In order to facilitate synthesis of these compounds, we devel-
oped a solid-phase synthesis method in which the terminal iso-
phthalic acid was linked to the resin using an amide linkage. The
diverse amino acids were then attached as methyl esters and
subsequently converted to the hydrazide followed by coupling
of the epoxide electrophile (Figure 2B). Use of a PEG-based
Rink resin permitted the use of methanol as the solvent for the
hydrazide formation but ultimately led to a terminal amide after
cleavage from the resin. Attempts to transfer this methodology
to a PEG-based Wang resin were unsuccessful as treatment
with hydrazine appeared to cleave the dipeptide from the resin.
Thus, unlike the original VEA260 compound that contains
a terminal carboxylic acid, all of the resulting library compounds
contain a terminal amide. We also synthesized VEA389, which is
the amide analog of VEA260 in order to determine the impact of
conversion of the terminal acid group to an amide. The P3 library
was synthesized in a similar manner, except that standard
Fmoc-protected amino acids were attached the Rink resin fol-
lowed by coupling of monomethyl terephthalic acid and conver-
sion to the azide.
Design and Synthesis of AOMK Inhibitor Library
Peptide AOMKs have been successfully used as covalent, irre-
versible probes of multiple classes of cysteine protease (Berger
et al., 2006; Bromme et al., 1994; Sexton et al., 2007). Further-
more, these compounds can be readily synthesized using
solid-phase synthesis methods (Kato et al., 2005). Therefore,
we decided to explore the use of the AOMK as an alternative
electrophile for hSENP inhibitors. For our first library, we retained
the overall structure of VEA260 and JCP666 but used a glycine or
aspartic acid residue in the P1 AOMK position (Figure 3A).
Furthermore, because we determined that bulky aromatic resi-
dues near the reactive electrophile enhanced binding, we
synthesized compounds that contained AOMKs with O-acyl
groups increasing in size. Finally, we included a nitro-phenol in
the P3 position to replace the isophthalic acid to explore diversity
in this position. We were able to synthesize this library of seven
compounds using standard solid-phase synthesis methods
already reported for the other classes of AOMK-based inhibitors
and activity-based probes (Kato et al., 2005). In addition, we also
generated a small library of peptide AOMKs based on natural
amino acid sequences. Data from positional scanning substrate
libraries suggest that hSENPs 1–5 show a preference for the
QTGG sequence which corresponds to the conserved cleavage
site on all three SUMOs; however, hSENPs 6 and 7 prefer the
LRGG sequence common to ubiquitin and Nedd8 (Drag et al.,
2008). Therefore we synthesized both of these sequences
with various truncations of the native SUMO sequence (Fig-
ure 3B). For all of these natural peptide AOMKs, we used a large
O-acyl-anthracene group in the hopes of improving potency.724 Chemistry & Biology 18, 722–732, June 24, 2011 ª2011 ElsevierThese peptide AOMKs are particularly interesting compounds
because they are mimetics of the peptide vinyl sulfone inhibitors
previously reported as hSENP inhibitors (Borodovsky et al.,
2005). Therefore, they allow direct comparison of the utility of
the AOMK and VS reactive groups for this class of proteases.
Screening of Compound Libraries against Recombinant
hSENPs
We initially screened all of the newly synthesized inhibitors for
activity against a number of human SENPs. Humans have six
SENPs that are responsible for both iso- and endo-peptidase
processing of four human SUMO proteins. While the exact bio-
logical roles of each SENP are not well defined, each has
different levels of iso- and endo-peptidase activity as well as
different specificities for the various hSUMOs (Mikolajczyk
et al., 2007). Because the original Pro-SUMO processing assay
is rather tedious and not suitable for use with large numbers of
compounds, we decided to screen our libraries using fluorogenic
substrates that could be analyzed using a simple plate reader
assay. We used the coumarin-based substrates, Ac-QTGG-
AFC for hSENPs 1, 2, and 5 and Ac-LRGG-AFC for hSENPs
6 and 7 (Drag et al., 2008). Human SENP3 was not screened in
this assay due to low solubility and poor activity of the recombi-
nant enzyme. Because we had a large number of initial
compounds and needed to perform the assay in triplicate, we
initially used a single, high concentration of each compound to
preincubate with the enzyme for 1 hr followed by measurement
of the residual activity using the reporter substrates. From
these data, we could determine relative inhibitor potency by
comparing percentage of inhibition of the target protease for
each of the library compounds (see Figures S1 and S2 available
online). The results of the screens for both the aza-epoxide and
AOMK libraries against all five hSENPs could then be plotted as
a heatmap that allows easy comparison of the complete data set
(Figure 4).
From the SAR data set, we observed several general trends
that could be used in our efforts to identify the most optimal
inhibitors for conversion to ABPs. First, we found that conversion
of the terminal acid of VEA260 to an amide resulted in a signifi-
cant loss in overall activity of the compounds (compare
VEA260 to VEA389). Since all of our aza-epoxides were synthe-
sized using the solid-phase method that resulted in the genera-
tion of a terminal amide, they were all either equal or less potent
than the original lead compounds. Interestingly, VEA422, which
contains a P3 aspartic acid showed similar potency to the parent
VEA260, suggesting that a negative charge in this general region
may be important for target binding. We also found that several
of the most potent aza-epoxides contained a threonine residue
in either the P2 or P3 positions. This suggests that there may
be key binding interaction with the enzyme at the S3 pocket
that normally binds the P3 threonine of the native SUMO
substrate.
From the AOMK library A, we determined that potency of
the compounds dramatically increased as the ring size of the
O-acyl group was increased from phenyl to naphthyl to anthra-
cene. This finding is consistent with the observed trend in
the aza-epoxides and suggests that significant contacts are
required in what is likely to be the side of the active site that
accommodates the prime-side sequence of the substrate. ThisLtd All rights reserved
Figure 2. Generation of a Library of Peptide Aza-Epoxides Based on VEA260
(A) Structures of the P2 and P3 libraries alongwith the structure of VEA389, the direct analog of VEA260 containing a terminal amide in place of the carboxylic acid.
(B) Scheme for synthesis of the P2 library. The epoxide electrophile building block (1) is shown.
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Figure 3. Structures of Acyloxymethyl Ketone (AOMK) Inhibitor
Libraries
(A) Structures of compounds from scaffold A containing the original P2
element of VEA260 and variable P1 and P3 elements. Inhibitors were
synthesized as described in the Supplemental Experimental Procedures.
Scaffold A was used to assess aryl group size, P1 aspartic acid versus glycine,
and importance of capping group.
(B) Structures of scaffold B AOMKs based on the natural amino acid sequence
found in SUMO and Ubiquitin.
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cessing isopeptides that contain a large protein substrate in
this prime-side region. In addition, the SAR data confirmed the
lack of preference for a P1 aspartic acid residue found in the
original JCP666. In fact, the P1 glycine AOMKsweremore potent
than the P1 aspartic acid AOMKs. This result is not surprising
given the fact that SENPs bind to substrates with a P1 glycine.
Finally, the results from the natural peptide AOMKs in library
B demonstrated the need for an extended peptide to facilitate
binding in the SENP active site. Specifically, we found that the
tetrapeptide (VEA499) and pentapeptide (VEA500) inhibitors
based on the natural sequence of hSUMO1 were substantially
more potent than the tripeptide (VEA498) equivalent. In addition,726 Chemistry & Biology 18, 722–732, June 24, 2011 ª2011 ElsevierVEA561 which contains the sequence of ubiquitin, was most
potent toward hSENP6 and hSENP7, consistent with the pub-
lished specificity of these proteases (Drag et al., 2008). Overall,
our results suggested that the extended peptide AOMKs based
on the natural SUMO sequence were most potent followed
closely by the AOMKs containing parts of the JCP666 scaffold.
To further characterize and more accurately rank the best in-
hibitors identified in the fixed concentration screen, we selected
the most active compounds from the P2/P3 aza-epoxide and
AOMK libraries and determined IC50 values for hSENP1, 2, 6,
and 7 using the fluorogenic substrate assay (Table 1; Figure S3).
Due to the low activity and limited solubility of hSENP5, IC50
values could not accurately be determined. The results revealed
that VEA260 was the most potent aza-epoxide inhibitor for
hSENP1, 2, and 7 and none of the aza-epoxides were able to
inhibit hSENP6. The AOMK based on the ubiquitin sequence
(VEA561), however, was the most potent overall inhibitor against
both hSENP6 and hSENP7, while the AOMK with the QTGG
specificity sequence (VEA499) was most potent overall for
hSENP1 and hSENP2.
We also wanted to test the potential for cross-reactivity of both
the epoxide and AOMK classes of inhibitors against related
proteases. Specifically, the AOMK inhibitor VEA561 has the
sequence LRGG-AOMK which matches the sequence found
on the C terminus of Ubiquitin and NEDD8. We therefore tested
VEA260, VEA499 (QTGG) and VEA561 (LRGG) against the puri-
fied human DUB UCHL3 and human SENP8 (a deNEDDylase)
to determine if the compounds were active against these off-
targets (see Figure S4). Interestingly, VEA260 showed virtually
no activity against either enzyme and the two AOMK probes
show only activity against hSENP8. We also confirmed that
VEA401 did not block labeling of DUBs in HEK293 cell lysates
by the HA-Ubvme probe (Figure S4), again suggesting that
the best SENP inhibitors do not have significant activity against
DUBs.
Although the AOMK-based inhibitors were generally active as
SENP inhibitors, we were concerned that these compoundsmay
not gain access to the SENPs due to overall low cell permeability.
We therefore tested our best AOMK compound with the least
peptide character, VEA401 in intact cells. Specifically, we
treated intact HeLa cells with VEA401 for 3 hr and then labeled
endogenous SENPs in lysates using a full-length SUMO2 probe
(HA-SUMO2-VME) (Figure S5). These results suggested that the
compound failed to gain sufficient access to either hSENP1 or
hSENP6 to block labeling by the HA-SUMO-VME probe. In addi-
tion, we were not able to find conditions in which we could treat
cell lysates with VEA401 and block labeling of endogenous
SENP1 or SENP6 by the HA-SUMO2vme probe. This is likely
due to the low levels of stable and active SENPs in lysates and
the overall slow binding of the AOMK compounds compared
with binding full-length SUMO probes. We therefore feel that
the AOMK probes will require further development in order to
be made sufficiently cell permeable to allow complete inhibition
of SENP targets.
Design and Synthesis of ABPs
One of primary goals of this study was to develop new reagents
that could be used as activity-based probes of hSENP activity.
We therefore decided to synthesize a series of biotin and Cy5Ltd All rights reserved
Figure 4. Activity of Aza-Epoxide and
AOMK Inhibitors against Recombinant
hSENP Proteases
Recombinant purified DNhSENPs1, 2, 5, 6, and 7
were incubated with 50 mM inhibitors. After addi-
tion of either Ac-QTGG-AFC for DNhSENPs 1, 2,
and 5 or Ac-LRGG-AFC for DNhSENPs 6 and 7,
the AFC production at 405 nm/510 nm for 10–
60 min was measured using a fluorescence plate
reader. Activity relative to the DMSO-treated
control was determined and average values from
triplicate runs are shown as a heat map where red
indicates 100% inhibition and white indicates 0%
inhibition. See also Figures S1 and S2.
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and aza-epoxide compounds identified in our SAR screen (Fig-
ure 5A). In addition, we synthesized a previously reported
biotin-labeled pentapeptide vinyl sulfone (Bio-EQTGG-VS) and
a vinyl methyl ester (Bio-QQTGG-VME) for comparison with
our newly identified compounds. Before using these compounds
as probes, we first tested them for potency against all the
hSENPs in our fluorogenic substrate assay (Figure 5B; Figure S6).
As expected, the AOMK probe VEA505 was most potent. The
aza-epoxide probe VEA355 also showed reasonable potency
against primarily hSENP1 and 2. Notably, the VS and VME
probes showed almost no inhibitory activity even at the highest
concentration of the assay.
We next tested the ability of the probes to label the recombi-
nant hSENPs. We added each of the probes to recombinant
hSENP1 and 2 and monitored labeling by analysis by SDS-
PAGE followed by blotting for biotin or scanning for fluorescence
(Figure 5C). In addition, we pretreated the recombinant enzymes
with the inhibitor versions of the probes as well as with the
general cysteine alkylating agent N-ethylmaleimide (NEM) to
block the active site. These results indicated that both the
aza-epoxide and AOMK probes efficiently labeled both hSENPs.
To confirm that labeling was due to modification of the active
site cysteine, we also labeled a mutant hSENP2 in which the
active site cysteine was converted to serine (hSENP2 C548S,
Tables S1 and S2). As expected, the AOMK probe VEA505 no
longer was able to label the mutant protease, while aza-epoxide
probe VEA355 showed a faint labeling suggesting that it may be
nonspecifically modifying noncatalytic cysteine residues. The
Cy5-labeled version of VEA355 also showed what appeared to
be a doublet of bands, again suggesting that it might be modi-
fying multiple cysteine residues resulting in different migration
in the gel. Interestingly, neither the previously reported vinyl
sulfone nor the vinyl methyl ester probes labeled either of the
hSENP proteases, consistent with their inability to inhibit the
recombinant proteases in the substrate assay. We also moni-
tored the kinetics of enzyme labeling over a period of 30 min to
7 hr (Figure 5D). These results demonstrated that labeling by
the AOMK-based probe VEA505 was relatively fast with labeling
detectable at the first time point for hSENP2. However, by
comparison the aza-epoxide probe showed slower labeling of
the enzyme. Interestingly, we also observed a slight upward shift
in mobility over time when labeling with Cy5-VEA355 consistent
with labeling multiple cysteine residues leading to a change in
migration in the gel. Based on these findings, it seemed thatChemistry & Biology 18,the AOMK probe was more suited for use as an ABP since it
reacted faster and showed less nonspecific labeling compared
with the aza-epoxide probe.
Labeling of hSENP1 in Complex Proteomes
As a final test to determine the selectivity of our ABPs for hSENP
proteases, we evaluated their ability to label a target hSENP in
a complex proteome. For this study, we added the recombinant
hSENP1 to total lysates from HEK293 cells. We then labeled the
lysates with a serial dilution of biotinylated or fluorescent aza-
epoxide and AOMK probes (Figure 6A). These results demon-
strated that the aza-epoxide probes were highly reactive and
produced high background labeling even at the lowest probe
concentration tested. Furthermore, we were not able to detect
any labeling of the hSENP for either the fluorescent or biotin-
labeled aza-epoxide probes. The AOMK, on the other hand,
produced clean labeling of the hSENP with only moderate back-
ground observed for high concentrations of the biotin probe.
Addition of the Cy5 probe produced clean labeling of the hSENP
that could be detected with less than 1 mM probe concentration.
We found that the biotin-VEA505 was also able to label hSENP1
at similar concentrations of the probe relative to the Cy5 version
of the probe. We also tested the activity of the biotin and Cy5
probes in the ProSUMO processing assay (Figure S7). Interest-
ingly, these data suggest that the Cy5 version of the probe
was able to block substrate processing more effectively than
the biotin version. Finally, for comparison, we performed the
same labeling experiment using the full-length SUMO probes
containing a C-terminal vinyl sulfone or vinyl methyl ester and
anHA tag (Figure 6B). As expected these probes produced clean
labeling of the target SENP with the VME probe showing similar
selectivity and sensitivity as the Cy5-VEA505. As a final test of
sensitivity, we used the biotin and Cy5 versions of VEA505 to
label recombinant hSENP1 that has been added to cell extracts
at a range of concentrations relative to the background pro-
teome (Figure S8). These data confirm that both probes have
similar sensitivity and can label as little as 100 nM of the enzyme
in a complex proteome. These results suggest that probes based
on the peptide AOMKs are valuable new ABPs that can be as
efficient and selective as the full-length protein-based probes.
SIGNIFICANCE
The process of protein SUMOylation and deSUMOylation is
dynamic. Therefore, the SENP proteases involved in the722–732, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 727
Table 1. IC50 Values of Most Potent Aza-Epoxide and AOMK Inhibitors
IC50 Values (mM)
hSENP1 hSENP2 hSENP6 hSENP7
JCP-666
13.8 ± 1.0 7.0 ± 0.4 >100 >70
VEA-260
7.1 ± 0.6 3.7 ± 0.2 >100 36.5 ± 4.7
VEA-417
32.5 ± 2.8 13.1 ± 1.3 >100 >70
VEA-422
22.4 ± 2.1 10.4 ± 0.7 >100 >70
VEA-401
23.1 ± 1.6 13.4 ± 1.2 >40 >20
VEA-499
3.6 ± 0.3 0.25 ± 0.03 >60 >100
VEA-500
>20 0.86 ± 0.1 >40 >100
VEA-561
>25 5.7 ± 1.6 4.2 ± 0.6 4.3 ± 0.7
Recombinant purified ΔNhSENPs 1, 2, 6, and 7 were incubated with inhibitors (195 nM to 100 mM). After addition of either Ac-QTGG-AFC for
ΔNhSENPs 1 and 2 or Ac-LRGG-AFC for ΔNhSENPs 6 and 7, AFC production was measured in triplicate using a fluorescence plate reader at
405 nm/510 nm for 10–60 min. Activity relative to the DMSO-treated control was determined and IC50 values calculated using GraFit 6 as described
in Experimental Procedures. See also Figure S3.
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Figure 5. Development of Activity-Based Probes for hSENPs Based on the Most Potent AOMK and Aza-Epoxide Inhibitors
(A) Structures of the AOMK and aza-epoxide probe scaffolds along with the peptide vinyl sulfone and vinyl methyl ester probes. For each probe, the R group
was either a biotin tag or Cy5 fluorescent tag as indicated in the name of the compound.
(B) Heat maps showing the activity of all the biotin versions of the probes (50 mM) against the recombinant hSENPs.
(C) Labeling of recombinant hSENP1 and hSENP2.DNhSENPs 1 and 2 or the catalytically deadmutantDNhSENP2C548S (0.5 mM)were labeledwith probe (1 mM)
after pretreatment with either with vehicle (–) or with VEA260 (epoxide inhibitor, 50 mM), VEA499 (AOMK inhibitor, 50 mM), or N-ethylmaleimide (NEM, 20 mM)
as indicated. Proteins were resolved by SDS-PAGE and labeling visualized by biotin affinity blotting using horseradish peroxidase-conjugated streptavidin for
the biotinylated probes. Cy5 probe labeling was resolved by SDS-PAGE and visualized using a flatbed scanner.
(D) Purified recombinant DNhSENPs 1 and 2 (0.5 mM) were treated with probe (1 mM) for increasing time (30 min to 7 hr). Samples were visualized as described
above. See also Figure S4.
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Figure 6. Labeling of Recombinant hSENP1 in Complex Proteomes
(A) Recombinant DNhSENP1 was spiked into hypotonic HEK293 cell lysates as 0.1% of the total protein mixture (25 ng DNhSENP1 in 25 mg of lysate). The spiked
lysate was treated with decreasing concentrations of probes (Bio-VEA355, Bio-VEA505, Cy5-VEA355, and Cy5-VEA505) for 1 hr at 37C. Proteins were resolved
by SDS-PAGE and visualized as described above.
(B) Recombinant DNhSENP1 spiked into hypotonic HEK293 cell lysates was treated with decreasing concentrations of apparent active full-length SUMO VS and
VME probes. Proteins were resolved by SDS-PAGE and visualized by western blot using an anti-HA antibody.
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from substrates are fundamental for a number of biological
processes regulated by SUMOylation. Unfortunately, there
are no optimal methods to temporally regulate the activity
of SENPs. Current reagents for studying SENP activity
require a full-length protein with an electrophile for covalent
modification of the proteases. In this study, we present two
new small molecule scaffolds that can be used as inhibitors
and activity-based probes of the hSENPs. Our results
suggest that peptide aza-epoxides are relatively efficient
inhibitors of various SENPs, but these reagents show high
nonspecific labeling properties when used in complex
proteomes. Peptide AOMKs containing a large aromatic
O-acyl group, on the other hand, are covalent inhibitors
that also function as highly selective probes of SENP
activity. While further work is required to increase the
potency of these compounds, we believe that they are an
important new class of reagents for the study of SENP
function.
EXPERIMENTAL PROCEDURES
Synthetic Protocols
See Supplemental Experimental Procedures.
Cloning and Expression of hSENP1, 2, 5, 6, and 7
All final constructs and primers are summarized in Tables S1 and S2. The
catalytic mutant of hSENP2 (C548S) was generated by PCR-SOE (primers
#1–4) and ligated into the pET28a vector for expression. All constructs were
expressed in BL21(DE3) Escherichia coli (OD600 = 0.6; 0.1 mM IPTG) for
3 hr at 30C, lysed in 50 mM HEPES (pH 7.4), 100 mM NaCl, 5% glycerol,
5% sucrose, immobilized on Ni2+-NTA agarose (QIAGEN), and eluted with
stepwise fractions of lysis buffer (50 mM HEPES [pH 7.4], 100 mM NaCl, 5%
glycerol, 5% sucrose) supplemented with 20–200 mM imidazole. The hSENPs
were prepared as previously described (Mikolajczyk et al., 2007).
ProhSUMO Cleavage Assays
SUMO-pro cleavage assays were performed as previously described (Miko-
lajczyk et al., 2007). In brief, 100 nM hSENP1 in reaction buffer (50 mM Tris
[pH 7.4], 5 mM NaCl, 5 mM DTT) was pretreated with inhibitor (JCP665-8)
for 30 min at 37C and then allowed to cleave SUMO-pro protein for 1 hr at
37C. Proteins were separated by SDS-PAGE and visualized by Gelcode
Blue protein stain reagent (Pierce).
Fluorogenic Substrate Assay
The fluorogenic substrate library screen was performed as described previ-
ously (Drag et al., 2008). In brief, hSENP1 (final concentration 2 mM) in low
salt Tris buffer (50 mM Tris [pH 8.0], 20 mM NaCl, 10 mM DTT) was preincu-
bated for 1 hr at 37C with inhibitor (50 mM final concentration) followed by
addition of substrate (100 nM). Fluorophore release (AFC) was monitored for
30 min at 37C with an excitation of 405 nm and emission at 510 nm. Rates
of cleavage were determined as the slope of the linear line representing
RFU/min. The DMSO-treated sample was set as 100%activity, and the activity
of the other samples was determined relative to this value. All values are the
average of independent triplicates.
IC50 Determinations
IC50’s for the inhibitors were determined by serial dilution of the compounds in
the fluorogenic assay described above. The assay was repeated three or four
times per compound and the IC50 determined using Graphfit software.
Time Course of Labeling of Recombinant hSENP1 and 2 with
Activity-Based Probes
Recombinant DhSENP1 or 2 was diluted to 0.5 mM in reaction buffer (50 mM
Tris [pH 7.4], 20 mM NaCl, 5 mM DTT) and treated with probe (1 mM finalChemistry & Biology 18,concentration of Bio-EQTGG-VS, Bio-QQTGG-VME, Bio-VEA505, Bio-
VEA355, Cy5-VEA505, Cy5-VEA355) for varying time (30 min to 7 hr) at
37C. Proteins were separated by SDS-PAGE. Fluorescent gels were scanned
using a Typhoon 9400 flatbed laser scanner (GE-Healthcare). All other gels
were visualized by biotin affinity blotting using horseradish peroxidase-conju-
gated streptavidin.
Labeling and Competition for Recombinant hSENP1 and 2 Activity
with Activity-Based Probes
Recombinant DhSENP1 or 2 or DhSENP2 C548S was diluted to 0.5 mM in
reaction buffer (50 mM Tris [pH 7.4], 20 mM NaCl, 5 mM DTT) and treated
with either DMSO, VEA260, VEA499 (both 50 mM final concentration) or N-eth-
ylmaleimide (20 mM final concentration) for 1 hr at 37C. Labeling was carried
out with 1 mM final probe concentration (Bio-EQTGG-VS, Bio-QQTGG-VME,
Bio-VEA505, Bio-VEA355, Cy5-VEA505, Cy5-VEA355) for 1 hr at 37C.
Proteins were separated by SDS-PAGE. Fluorescent gels were scanned using
a Typhoon 9400 flatbed laser scanner (GE-Healthcare). All other gels were
visualized by biotin affinity blotting using horseradish peroxidase-conjugated
streptavidin.
Labeling of Recombinant hSENP1 Spiked into HEK293 Cell Lysates
Recombinant DhSENP1 (25 ng) was added to HEK293 cell lysates (25 mg) in
reaction buffer (50 mM Tris [pH 7.4], 20 mM NaCl, 5 mM DTT) and treated
with serial dilution of probe (Bio-VEA505, Bio-VEA355, Cy5-VEA505, Cy5-
VEA355, HA-SUMO1-VME, HA-SUMO1-VS) for 1 hr at 37C. Proteins were
separated by SDS-PAGE. Fluorescent gels were scanned using a Typhoon
9400 flatbed laser scanner (GE-Healthcare). Biotinylated probes were visual-
ized by biotin affinity blotting using horseradish peroxidase-conjugated strep-
tavidin and full-length SUMO probes were visualized using an anti-HA
antibody.
Lysate Preparation
Lysates of HEK293 cells were prepared from cells grown as a 90% confluent
monolayer. The cells were washed with PBS before being scraped and
transferred to an Eppendorf tube. The cells were spun down at 2000 rpm for
4min and thePBSwas removed. An equivalent volumeof hypotonic lysis buffer
(20 mM Tris [pH 7.4], 5 mM NaCl, and 5 mM DTT) was added to the pellet. The
mixture was allowed to sit on ice for 10 min before mechanical lysis through
a 26.5 gauge needle. The mixture was spun down at maximum speed for
30 min at 4C. The supernatant was transferred and quantified to be 8 mg/ml.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Supplemental Compound Characterization, eight figures, and two tables and
can be found with this article online at doi:10.1016/j.chembiol.2011.05.008.
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